AI assistant
BridgeBio Pharma, Inc. — Director's Dealing 2025
Sep 9, 2025
30604_dirs_2025-09-08_fdd5a897-44a0-46d1-b6b2-94638a6de3b2.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: BridgeBio Pharma, Inc. (BBIO)
CIK: 0001743881
Period of Report: 2025-09-05
Reporting Person: MCCORMICK FRANK (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-09-05 | Common Stock | M | 74000 | $11.92 | Acquired | 157275 | Direct |
| 2025-09-05 | Common Stock | S | 74000 | $53.156 | Disposed | 83275 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2025-09-05 | Stock Option (Right to Buy) | $11.92 | M | 74000 | Disposed | 2033-02-20 | Common Stock (74000) | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 879979 | Indirect |
Footnotes
F1: Represents the weighted average sale price of the shares sold from $52.96 to $53.39 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
F2: The stock option vests and becomes exercisable in three annual installments after February 21, 2023, with a final vesting date of February 21, 2026, subject to the Reporting Person's continued service on the Issuer's Board of Directors through each such date.